antiviral;tlr7

Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

Resiquimod (R848) is an agonist of Toll-like receptors 7 and 8 (TLR7/TLR8) that induces the upregulation of cytokines including TNF-α, IL-6, and IFN-α. It possesses immunomodulatory, antitumor, and antiviral activities, and can be used to induce models of myocarditis and systemic lupus erythematosus (SLE).

Imiquimod 2HCl is a toll-like receptor 7 (TLR7) agonist and immune modulator with antiviral and antitumor activities. It can be used to establish psoriasis-like mouse models and for the study of periorbital skin cancer, pemphigus foliaceus, and COVID-19.

Imiquimod hydrochloride (R 837 hydrochloride) is a selective toll-like receptor 7 (TLR7) agonist and immune response modulator with antiviral and antitumor activities. It is used in the study of external genital warts, perianal warts, cancer, COVID-19, pemphigus foliaceus, skin cancer, and psoriasis, and is commonly employed to establish psoriasis models.

Imiquimod maleate (R 837 maleate) is a toll-like receptor 7 (TLR7) agonist and immune response modifier with antiviral and antitumor activities. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and can induce psoriasis-like skin lesions in mice, commonly used to establish psoriasis models.

Enpatoran hydrochloride (M5049 hydrochloride) is an orally active, selective, and potent TLR7/8 inhibitor with antiviral activity for the study of autoimmune diseases and COVID-19 pneumonia.

Ruzotolimod (RO7020531) is an orally active Toll-like receptor 7 agonist that suppresses WHV replication and, in combination with RO-7049389, significantly reduces AAV-HBV viral load, while also serving as an experimental immunomodulatory agent for studying antiviral innate immune responses and therapeutic strategies relevant to SARS-CoV-2 and COVID-19 infection models.

TLR7/8 agonist 1 is a toll-like receptor TLR7/TLR8 agonist with anticancer and antiviral activities and can be used to study immune-related diseases.

Anti-TLR7 Antibody is a humanized monoclonal antibody targeting Toll-like receptor 7 (TLR7). TLR7 is a pattern recognition receptor primarily located on endosomal membranes that recognizes single-stranded RNA (ssRNA), playing a pivotal role in antiviral immune responses and autoimmune diseases such as Systemic Lupus Erythematosus (SLE). This antibody specifically binds to TLR7, blocking its activation by ligands (e.g., viral RNA or synthetic agonists) and subsequently inhibiting the downstream MyD88-dependent signaling pathway and the production of Type I interferons (IFN-α/β). By modulating TLR7 signaling, Anti-TLR7 Antibody serves as a valuable tool for investigating viral infection mechanisms and therapeutic strategies for autoimmune disorders.

Imiquimod-D9 is the deuterated form of Imiquimod. Imiquimod (T0134) (R 837) functions as a toll-like receptor 7 (TLR7) agonist, serving as an immune response modifier. It demonstrates antiviral and antitumor effects in vivo and is applicable in research related to external genital and perianal warts, cancer, and COVID-19.

Imiquimod (Standard) is the standard substance of Imiquimod, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

3'-O-(2-Methoxyethyl)guanosine is a guanine nucleoside analogue with immunostimulatory activity. It can induce type I interferon production in various animal models and thereby exert antiviral effects. Related studies have confirmed that the functional activity of guanosine analogues depends on the activation of Toll-like receptor 7 (TLR7).